Case: 23-2317 Document: 25 Page: 1 Filed: 03/11/2025

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________ IN RE: ENTRESTO (SACUBITRIL/VALSARTAN) ------------------------------------------------- NOVARTIS PHARMACEUTICALS CORPORATION, Plaintiff-Appellant v. NANJING NORATECH PHARMACEUTICAL CO., LTD., Defendant-Appellee ______________________ 2023-2317, 2023-2319 ______________________ Appeals from the United States District Court for the District of Delaware in Nos. 1:20-md-02930-RGA and 1:23- cv-00401-RGA, Judge Richard G. Andrews. ______________________ ON MOTION ______________________ Before LOURIE, TARANTO, and STOLL, Circuit Judges.

PER CURIAM.

ORDER Case: 23-2317 Document: 25 Page: 2 Filed: 03/11/2025

2 IN RE: ENTRESTO (SACUBITRIL/VALSARTAN)

Upon consideration of appellant’s motion to stay the fi- nal judgment pending appeal, appellee’s motion to dismiss, the parties’ joint statement that if the invalidity judgment in Appeal No. 2023-2218 “is not affirmed,” “the judgment in this case should be vacated and the case remanded for further proceedings,” ECF No. 9 at 3, and this court’s re- cent decisions and orders in Appeal No. 2023-2218 revers- ing the relevant aspect of the judgment and enjoining the defendants in that case from launching their generic drug until issuance of mandate in that appeal, IT IS ORDERED THAT: (1) The district court’s judgment is vacated and the cases remanded to the district court for further proceed- ings. (2) The district court’s judgment is stayed until issu- ance of mandate in Appeal Nos. 2023-2317, 2023-2319. (3) Any pending motion otherwise is denied. (4) Each party shall bear its own costs.

FOR THE COURT

March 11, 2025 Date